Gene therapy of cancer represents a promising but challenging area of therapeutic research. The discovery of radiation-inducible genes led to the concept and development of radiation-targeted gene therapy. In this approach, promoters of radiation-inducible genes are used to drive transcription of transgenes in the response to radiation. Constructs in which the radiation-inducible promoter elements activate a transgene encoding a cytotoxic protein are delivered to tumors by adenoviral vectors. The tumoricidal effects are then localized temporally and spatially by X-rays. We review the conceptual development of TNFeradet, an adenoviral vector containing radiation-inducible elements of the early growth response-1 promoter upstream of a cDNA encoding human tumor necrosis factor-a. We also summarize the preclinical work and clinical trials utilizing this vector as a treatment for diverse solid tumors.
TNF-a, radiation-induced gene expression, and the Egr-1 promoter
Paracrine effects of cytokines on tumor cells Hallahan et al. 1, 2 described experiments in which the media of x-irradiated human tumor cells was toxic to cells in other cell cultures. These effects were proposed to be due to the induction of tumor necrosis factor-alpha (TNF-a) genes and suggested that TNF-a might be a useful radiosensitizing protein. In separate investigations, we identified the Egr-1 gene as inducible by exposure to ionizing radiation (IR) via radical oxygen intermediate (ROI) formation and that the serum response or CArG box [CC(A þ T-rich)6GG] elements in the 5 0 promoter of the gene are the sequences necessary and sufficient for radioinduction. 3 Integration of these experimental results describing regulation of Egr-1 transcription and TNF-a induction suggested that a chimeric construct that includes the inducible elements of the Egr-1 promoter upstream to TNF-a could be utilized for radiationtargeted gene therapy. [3] [4] [5] Spatial and temporal control of gene expression The finding that IR activates Egr-1 gene transcription provided the experimental basis for the design of a novel gene therapy strategy in which IR would regulate the spatial distribution and maintain temporal control of specified gene transcription. In this approach, the radiation responsive CArG elements of the Egr-1 promoter could drive the expression of a therapeutic transgene. TNF-a was a potential candidate because of both the cytotoxic effects of this protein and synergistic activity observed in combination with IR ( Figure 1) . 1, 2 The first set of experiments tested direct injection of leukemia cells transfected with the Egr-1.TNF construct in tumors formed by human SQ-20B radioresistant head and neck carcinoma cells. 5 Irradiation of the tumors was associated with IR-induced TNF-a expression, tumor regressions and cures without increasing systemic toxicity. This construct was also effective in overcoming radioresistance when transfected into a murine fibrosarcoma cell line using cationic liposomes. 6 To deliver the Egr-TNF construct to tumors in patients, we utilized a replicationincompetent adenovirus. This led to the development of Ad.Egr-TNF, which is the prototype adenoviral vector utilized in our laboratory as well as others. [7] [8] [9] [10] [11] Thus, Ad.Egr.TNF contains the Egr-1 promoter ligated upstream of the cDNA for human TNF-a. Importantly, treatment of radioresistant human epidermoid carcinoma, prostate, and glioma xenografts by direct intratumoral injection of Ad.Egr-TNF and fractionated IR resulted in induction of TNF-a and tumor radiosensitization. 7, 9, 10 Ad.Egr.TNF also improved the antitumor effectiveness of IR in the treatment of the radio-and TNF-resistant murine P4L fibrosarcoma tumors. 9 Notably, the combination of Ad.Egr.TNF and IR was not associated with increased local or systemic toxicity at therapeutically effective doses during the course of the experiments (30-60 days).
Histopathological analysis of tumors treated with the combination of Ad.Egr.TNF and IR revealed extensive intratumoral vessel thrombosis and tumor necrosis. By contrast, adjacent normal tissue vessels appeared unaffected. 7, 10 These data suggested that, in addition to direct tumor cytotoxicity, the tumor microvasculature is a potential target for the combined effects of IR and high intratumoral concentrations of IR-induced TNF-a. Subsequent studies demonstrated that elevated intratumoral TNF-a concentrations induce conversion of plasminogen to angiostatin, a thrombogenic by-product. 12 Notably, TNF and angiostatin disrupt the tumor vasculature 13 by mechanisms involving the aVb3 integrin31,32 and aVb3,33 respectively. Thus, the microvasculature changes observed with Ad.Egr.TNF and IR are likely due to IRinduced TNF expression and thereby in part increased intratumoral levels of angiostatin.
Chemoinduction of Ad.Egr-TNF vectors
Activation of the Egr-1 promoter in response to IR is mediated by DNA damage-and ROI-induced signaling to the CArG sequence. 3, 4, 14 We therefore hypothesized that other cytotoxic agents that induce DNA damage or ROIs might activate TNF-a transgene expression through the Egr-1 CArG sequences. In this regard, we first investigated cisplatin, an alkylating agent reported to produce both ROIs and DNA damage. 15, 16 Cisplatin and its analogues are used to treat a broad range of solid tumors, including esophageal, pancreatic, and colon adenocarcinomas. [17] [18] [19] Moreover, cisplatin is a documented radiosensitizer. 19 To test the hypothesis that a chemotherapeutic agent could activate Ad.Egr.TNF, Park et al. 20 infected tumors established with Seg-1 esophageal carcinoma cells or the PROb rat colon adenocarcinoma cells with Ad.Egr-TNF. The animals were then treated with cisplatin. There was a significant increase in TNF-a following exposure of the Ad.Egr-TNF-infected tumor cells to cisplatin both in vitro and in vivo (Figure 2a) . Significantly, exposure of Seg-1 cells to cisplatin resulted in a greater amount of TNF-a production than irradiation. To determine if cisplatininduced TNF-a production is specifically due to activation of the CArG elements of the Egr-1 promoter, transient transfection assays were performed using promoter constructs with deletion mutants of the Egr-1 promoter linked to luciferase. Cisplatin activated the Egr-1 promoter and this response was abrogated by deletion of the CArG sequences, indicating that, like IR, cisplatin induces signals that target the CArG elements. Xenografted tumors established from both cell lines demonstrated significant cisplatin-induced increases in TNF-a expression by both ELISA and real-time quantitative PCR. In addition, tumor regression of both Seg-1 and PROb tumors was significantly enhanced by the combination of Ad.Egr-TNF and intraperitoneal cisplatin compared with either treatment alone ( Figure 2b ). These results suggest that chemoinduction of Ad.Egr-TNFinfected solid tumors may be useful in a setting where cisplatin is a standard therapy.
To test the hypothesis that other classes of chemotherapeutic agents that induce ROIs would activate TNF-a production, Lopez et al. tested induction of Ad.Egr-TNF with cyclophosphamide, doxorubicin, 5-fluorouracil, gemcitabine, and paclitaxel in cell culture and in vivo.
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These agents and cisplatin were studied in PC-3 (human prostate cancer cell line) and PROb cells. Ad.Egr-TNF was activated by each of these agents in culture and in vivo ( Figure 3 ). In addition, the combination of the Ad.Egr-TNF and doxorubicin overcomes both doxorubicin and TNF-a resistance when combined in the treatment of PC-3 and PROb tumors (Figure 4) . A significant reduction in angiogenesis was also observed in PC-3 tumors exposed to Ad.Egr-TNF and doxorubicin than with either treatment alone.
To determine if the chemotherapeutic agents activate the Egr-1 promoter through generation of ROIs, the chemoinduction studies were performed in the presence of the ROI scavenger, N-acetylcysteine (NAC). 21 Increasing concentrations of NAC (10-30 mmol/l) significantly decreased induction of TNF-a protein following exposure to each of the chemotherapeutic agents. These data indicate that activation of Ad.Egr-TNF by different classes of chemotherapeutic agents is in large part mediated through ROI production.
Adenoviral vectors that target disseminated cancer are under development, but vectors that are useful for systemic targeting of cancer are not yet available. Thus, treatment of tumors by radio-and chemoinduction is presently limited to accessible sites of local disease. To assess chemoinduction in a model of local disease, we employed another chemotherapeutic agent, temozolomide, in experimental glioblastoma. 22 Yamini et al. administered this orally bioavailable alkylating agent after transduction of glioblastoma cells with Ad.Egr-TNF. The combination was associated with significant induction of TNF-a and cytotoxicity in vitro. The antitumor activity of Ad.Egr-TNF and temozolomide was tested in a hind-limb regression study. As shown in Figure 5a , there was a significant reduction in fractional tumor volume in the combination treatment group compared with either treatment alone. Importantly, evaluation of this combined therapy in an intracranial glioblastoma model resulted in a significant increase in median survival (Figure 5b) .
From these studies, we hypothesized that combining Ad.Egr-TNF with chemoradiation clinically could result in increases in the therapeutic ratios of these modalities In vivo chemoinduction of Ad.Egr-TNF in tumor xenografts. PC-3 (a) and PROb (b) xenografts were treated by intratumoral injection of 5 Â 10 9 pu Ad.Egr-TNF on days 0 and 1 and the indicated chemotherapeutic agents given on days 1 and 2 (cisplatin 9 mg/kg; cyclophosphamide 160 mg/kg; doxorubicin 15 mg/ kg; 5-FU 100 mg/kg; gemcitabine 500 mg/kg). Significant increases in TNF-a protein detected by ELISA was observed for all agents. and overcome inherent tumor radioresistance. Moreover, an additional benefit of Ad.Egr-TNF is the favorable toxicity profile found in preclinical models. 23 These findings led to the development and design of phase I clinical trials. 24 
Clinical trials evaluating IR with intratumoral Ad.Egr-TNF (TNFeradet)
Owing to the significant toxicity associated with the systemic (intravenous) administration of TNF-a, the clinical utility of this cytokine has been limited. Current clinical uses include isolated limb perfusion in combination with chemotherapy for patients with soft-tissue sarcoma or in-transit melanoma who face possible amputation for bulky, unresectable disease. 25, 26 TNFeradet in combination with radiation in patients with various solid tumors was first published as a phase I (toxicity) trial. 27 TNFeradet is a second generation E1-, partial E3-, and E4-deleted adenoviral vector carrying the transgene encoding for human TNF-a downstream of the Egr-1 promoter. TNFeradet was delivered to 36 patients with solid tumors accessible for repeated injections in whom radiotherapy was indicated. Histological tumor types included pancreas, head and neck, hepatocellular, breast, colorectal, and melanoma. Patients were given intratumoral TNFeradet injection weekly for 6 weeks at dose levels ranging from 4 Â 10 7 to 4 Â 10 11 particle-units (pu). Concomitant external beam radiotherapy began on week 2 of the study and was administered to equate a total dose range of 20-66.6 Gy. The radiotherapy regimen depended on both the tumor type and location as well as patient performance status. The typical regimen given was between 1.8 and 2.0 Gy daily Monday to Friday. There were no dose-limiting toxicities observed and only grade 2 constitutional symptoms such as fever, chills, and pain at the injection site were reported. There was also no significant systemic toxicity attributed to serum TNF-a levels. For example, serum TNF-a levels during treatment remained close to baseline (o50 pg/ml). Additionally, patient samples of blood, urine, and sputum all tested negative for the presence of TNFeradet. There were objective tumor responses in 14 of the 30 evaluable patients, including five patients who achieved complete responses. Three patients with melanoma, a classically radioresistant tumor, were among the complete responders. Three of the four patients with pancreatic cancer also demonstrated tumor shrinkage. There was also doserelated activity (TNFeradet) in that 12 of 22 patients (55%) had a complete (five) or partial (seven) response at the higher TNFeradet doses. In the lower dose group, only 2/8 (25%) patients had an objective tumor response. Comparison with the patients who received irradiation without TNFeradet demonstrated that TNFeradet increases antitumor activity in patients who received both treatments. Notably, patients in this study achieving complete response received far less than the accepted potentially curative dose of IR (70 Gy over 7 weeks) for these tumor types. The findings from this phase I trial indicated that TNFeradet and radiation is well tolerated and may be more effective than radiation alone.
A second phase I study evaluated the safety of intratumoral administration of TNFeradet in combination with IR in patients with large extremity soft-tissue sarcoma. 28 Soft-tissue sarcomas were selected for this study due to the sensitivity of these tumors to TNF-a seen in limb perfusion studies. 25 Additionally, soft-tissue sarcomas are easily accessible for repeated intratumoral injections of TNFeradet and are clinically radioresistant. TNFeradet was administered by intratumoral injection to 14 patients at doses ranging from 4 Â 10 9 to 4 Â 10 11 pu given twice during week 1 of the study and then once per week during weeks 2-5. The treatment during weeks 2-5 were concomitant with a radiation dose of 50 Gy. There were no dose-limiting toxicities and, only relatively mild constitutional symptoms (e.g. fever) were reported. One patient withdrew from the study following one intratumoral injection of 4 Â 10 11 pu due to grade 2 toxicity. Of the 13 patients evaluable for response, 11 (85%) had objective responses. There were two complete responses and nine partial responses. Of the 11 patients who underwent resection following the combination therapy, 10 (91%) had either a complete or a partial pathologic response. On pathologic analysis following resection, there was extensive intratumoral necrosis in treated tumors and no specimens with pathologic positive resection margins. Interestingly, little clinical tumor shrinkage was observed even in patients who had 100% pathological responses suggesting that a radiographic or molecular marker might be valuable in evaluating clinical responses to TNFeradet. This phase I trial confirmed that TNFeradet and radiation are well tolerated by patients and that this treatment can be effective for large tumors that are unlikely to respond to single modality therapy.
The antitumor activity of TNFeradet was encouraging in phase I studies, and now several phase II trials underway. A phase II dose escalation study in locally advanced, unresectable pancreatic adenocarcinoma has begun. Patients are receiving weekly intratumoral injections of increasing doses of TNFeradet via endoscopic ultrasound or percutaneously by CT or ultrasound-guided injection followed by 5 weeks of concomitant chemotherapy with 5-fluorouracil (5-FU) and radiotherapy (50.4 Gy). Tumor shrinkage has been demonstrated and survival is being assessed. Of the patients receiving 4 Â 10 11 pu of TNFeradet, 6/7 (86%) have shown 425% tumor shrinkage during the 6-month follow-up. Interim results demonstrate a greater than 15-month median survival in patients receiving high-dose TNFeradet (Neil Senzer, personal communication). Another phase II trial is underway in patients with adenocarcinoma of the esophagus. Patients are receiving a 5-week course of chemoradiation (45 Gy, 5-FU and cisplatin) and intratumoral injection of escalating doses of TNFeradet (4 Â 10 8 -4 Â 10 11 pu) by endoscopic ultrasound or endoscopy. Results from this trial are still pending, but thus far, there are several anecdotal reports of significant tumor response to the combination therapy. An increase in thromboembolic events was noted in patients with esophageal cancer and the trial has been suspended pending investigation of these potential side effects (Neil Senzer, personal communication). Currently, trials for patients with rectal cancer, metastatic melanoma, and soft-tissue sarcoma are also being initiated.
In summary, our data provide support for the hypothesis that gene transfer using a radiation-and chemo-inducible promoter in combination with these DNA-damaging agents may represent an effective way to exploit the anticancer activity of TNF-a without the limitations of systemic toxicity and thereby increase responsiveness of human tumors to conventional treatment.
